Results of an Open-Label Comparative Randomized Clinical Trial of Axoglatiran®  Fs (F-Sintez, Russia) Efficiency and Safety in Comparison With Copaxone®-Teva (Teva Pharmaceutical Industries Ltd., Israel) in Patients With Relapsing-Remitting Multiple Sclerosis

The article discusses the design and results of recently published study of an analog of the original glatiramer acetate. The necessity of the correct planning and analysis of the data of such studies is stressed, showing equal efficacy, tolerability and safety of analog and original drug. The optimal design of such studies, their duration, selection of primary endpoint, adequate assessment of clinical and MRI changes and side-effects are discussed. The authors reckon that it is impossible to plan studies the results of which are based on the design, i.e. the absence of differences from the original drug. The authors invite specialists in MS to participate in the discussion.

show abstract

The results of an open comparative retrospective trial of the course of multiple sclerosis during treatment with infibeta and other interferon-beta bioanalogues and glatiramer acetate

Fa¹,

Ti²,

Гранатов

et al. 2018

Z. nevrol. psikhiatr. im. S.S. Korsakova

Self Cite

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Results of an Open-Label Comparative Randomized Clinical Trial of Axoglatiran® Fs (F-Sintez, Russia) Efficiency and Safety in Comparison With Copaxone®-Teva (Teva Pharmaceutical Industries Ltd., Israel) in Patients With Relapsing-Remitting Multiple Sclerosis

Cited by 4 publications

References 6 publications

Axoglatiran® FS: Generic of Copaxone® Preparation Based on Glatiramer Acetate

Axoglatiran® FS: Generic of Copaxone® Preparation Based on Glatiramer Acetate

An analysis of clinical trials on the registration of similars of the original disease-modifying therapies

The results of an open comparative retrospective trial of the course of multiple sclerosis during treatment with infibeta and other interferon-beta bioanalogues and glatiramer acetate

Contact Info

Product

Resources

About